Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon 40,000 MMS in Pancreatic Exocrine Insufficiency
NCT00705978Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jun 2008
- Primary completion
- May 2010
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic exocrine insufficiency (EPI) comparing Creon 40,000 MMS with Placebo (2 arms). Primary endpoint: Coefficient of Fat Absorption at 7 days. Started Jun 2008; status: completed.
02
Drugs
LipaCreon
03
Conditions
pancreatic exocrine insufficiency (EPI)
Beyond the preview
Go deeper on NCT00705978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705978.